This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
33 results for: regulation-pharma
post featured image
Download a copy of our January monthly briefing, which covers key updates and insights in the following areas:  Pharmacies; Clinical...
post featured image
The FDA has denied two citizen petitions filed on behalf of the Informed Consent Action Network (ICAN) requesting the agency revoke its...
post featured image
We first wrote about the planned amendments to the Pharmaceutical Law and certain other acts (the so-called Verticalisation Act) in...
post featured image
The FDA recently published “Sameness Evaluations in an ANDA – Active Ingredients,” a new draft guidance detailing recommendations for...
post featured image
When clinical trials for new drug approvals fail to adequately represent racial and ethnic groups, there is a lost opportunity to collect...
post featured image
The Inflation Reduction Act (IRA) significantly impacts the US economic model for prescription drug innovation through the imposition of...
post featured image
Our EU Life Sciences Regulatory team led by Marco de Morpurgo and Nicola Landolfi have produced a guide on EU Pharma & Medical Device...
post featured image
In our latest report, we provide an update on the key legislative changes proposed and introduced in the pharmaceutical sector in Poland.
post featured image
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the European Federation of Pharmaceutical...
post featured image
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) issued a joint statement on the interchangeability of...
post featured image
Today, the European Commission adopted a proposal for a new Regulation on standards of quality and safety for substances of human origin...
post featured image
After a brief hiatus from the string of Warning Letters sent to 503B outsourcing facilities in mid- to late 2021, on June 7, 2022, FDA...
post featured image
For pharmaceutical companies, patent term extensions (PTEs) remain a fundamental means of compensating them for the erosion of the terms...
post featured image
The Medicines & Healthcare products Regulatory Agency (MHRA) has announced a new supervisory scheme as part of its process for monitoring...
post featured image
We stand today on the threshold of almost unimaginable progress in defeating diseases that have ravaged humans for millennia. New...
post featured image
Patent term extensions (PTEs) in Australia have been a hot topic over the past year.  On Friday, things got a lot hotter for patentees...